140 related articles for article (PubMed ID: 25612651)
81. Gene's co-expression network and experimental validation of molecular markers associated with the drug resistance of gastric cancer.
Qi W; Zhang Q
Biomark Med; 2020 Jun; 14(9):761-773. PubMed ID: 32715733
[No Abstract] [Full Text] [Related]
82. CircRNA: A new class of targets for gastric cancer drug resistance therapy.
Zheng Y; Li Z; Wang Y; Chen W; Lin Y; Guo J; Ye G
Pathol Oncol Res; 2023; 29():1611033. PubMed ID: 37065861
[TBL] [Abstract][Full Text] [Related]
83. Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway.
Ding W; Ju S; Jiang S; Zhu L; Wang Y; Wang H
Pathol Oncol Res; 2009 Dec; 15(4):693-701. PubMed ID: 19466596
[TBL] [Abstract][Full Text] [Related]
84. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics.
Che G; Yin J; Wang W; Luo Y; Chen Y; Yu X; Wang H; Liu X; Chen Z; Wang X; Chen Y; Wang X; Tang K; Tang J; Shao W; Wu C; Sheng J; Li Q; Liu J
Drug Resist Updat; 2024 May; 74():101080. PubMed ID: 38579635
[TBL] [Abstract][Full Text] [Related]
85. Extracellular Acidity-mediated Expression of cPLA2γ Confers Resistance in Gastric Cancer Cells.
Lim SC; Lee TB; Kang BS; Iy Han S
Anticancer Res; 2021 Jan; 41(1):211-218. PubMed ID: 33419815
[TBL] [Abstract][Full Text] [Related]
86. Aldolase A promotes cell proliferation and cisplatin resistance via the EGFR pathway in gastric cancer.
Gu M; Jiang B; Li H; Zhu D; Jiang Y; Xu W
Am J Transl Res; 2022; 14(9):6586-6595. PubMed ID: 36247245
[TBL] [Abstract][Full Text] [Related]
87. Mortalin/glucose-regulated protein 75 promotes the cisplatin-resistance of gastric cancer via regulating anti-oxidation/apoptosis and metabolic reprogramming.
Dai Y; Li F; Jiao Y; Wang G; Zhan T; Xia Y; Liu H; Yang H; Zhang J; Tang L
Cell Death Discov; 2021 Jun; 7(1):140. PubMed ID: 34117210
[TBL] [Abstract][Full Text] [Related]
88. APRIL Drives a Coordinated but Diverse Response as a Foundation for Plasma Cell Longevity.
Stephenson S; Care MA; Doody GM; Tooze RM
J Immunol; 2022 Sep; 209(5):926-937. PubMed ID: 36130130
[TBL] [Abstract][Full Text] [Related]
89. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
Spaety ME; Gries A; Badie A; Venkatasamy A; Romain B; Orvain C; Yanagihara K; Okamoto K; Jung AC; Mellitzer G; Pfeffer S; Gaiddon C
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31703394
[TBL] [Abstract][Full Text] [Related]
90. Cellular physiological approach for treatment of gastric cancer.
Shiozaki A; Ichikawa D; Otsuji E; Marunaka Y
World J Gastroenterol; 2014 Sep; 20(33):11560-6. PubMed ID: 25206263
[TBL] [Abstract][Full Text] [Related]
91. Role of the APRIL molecule in solid tumors.
Nowacka KH; Jabłońska E
Cytokine Growth Factor Rev; 2021 Oct; 61():38-44. PubMed ID: 34446365
[TBL] [Abstract][Full Text] [Related]
92. Clinical Issues-April 2019.
Ogg MJ; deKay K
AORN J; 2019 Apr; 109(4):508-516. PubMed ID: 30919417
[No Abstract] [Full Text] [Related]
93. Characteristic miR-24 Expression in Gastric Cancers among Atomic Bomb Survivors.
Naito Y; Oue N; Pham TT; Yamamoto M; Fujihara M; Ishida T; Mukai S; Sentani K; Sakamoto N; Hida E; Sasaki H; Yasui W
Pathobiology; 2015; 82(2):68-75. PubMed ID: 26045155
[TBL] [Abstract][Full Text] [Related]
94. NF-κB signaling mediates acquired resistance after PARP inhibition.
Nakagawa Y; Sedukhina AS; Okamoto N; Nagasawa S; Suzuki N; Ohta T; Hattori H; Roche-Molina M; Narváez AJ; Jeyasekharan AD; Bernal JA; Sato K
Oncotarget; 2015 Feb; 6(6):3825-39. PubMed ID: 25686825
[TBL] [Abstract][Full Text] [Related]
95. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.
Agirre X; Castellano G; Pascual M; Heath S; Kulis M; Segura V; Bergmann A; Esteve A; Merkel A; Raineri E; Agueda L; Blanc J; Richardson D; Clarke L; Datta A; Russiñol N; Queirós AC; Beekman R; Rodríguez-Madoz JR; San José-Enériz E; Fang F; Gutiérrez NC; García-Verdugo JM; Robson MI; Schirmer EC; Guruceaga E; Martens JH; Gut M; Calasanz MJ; Flicek P; Siebert R; Campo E; Miguel JF; Melnick A; Stunnenberg HG; Gut IG; Prosper F; Martín-Subero JI
Genome Res; 2015 Apr; 25(4):478-87. PubMed ID: 25644835
[TBL] [Abstract][Full Text] [Related]
96. Expression of Immune-Related and Inflammatory Markers and Their Prognostic Impact in Colorectal Cancer Patients.
An S; Kim SK; Kwon HY; Kim CS; Bang HJ; Do H; Kim B; Kim K; Kim Y
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511338
[TBL] [Abstract][Full Text] [Related]
97. A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence.
Toraih EA; Fawzy MS; Ning B; Zerfaoui M; Errami Y; Ruiz EM; Hussein MH; Haidari M; Bratton M; Tortelote GG; Hilliard S; Nilubol N; Russell JO; Shama MA; El-Dahr SS; Moroz K; Hu T; Kandil E
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077665
[TBL] [Abstract][Full Text] [Related]
98. CircARVCF Contributes to Cisplatin Resistance in Gastric Cancer by Altering miR-1205 and FGFR1.
Zhang R; Zhao H; Yuan H; Wu J; Liu H; Sun S; Zhang Z; Wang J
Front Genet; 2021; 12():767590. PubMed ID: 34899853
[No Abstract] [Full Text] [Related]
99. NF-κB in Gastric Cancer Development and Therapy.
Chaithongyot S; Jantaree P; Sokolova O; Naumann M
Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440074
[TBL] [Abstract][Full Text] [Related]
100. The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer.
Sun J; Wang X; Zhang Z; Zeng Z; Ouyang S; Kang W
Front Oncol; 2021; 11():641304. PubMed ID: 33937042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
